Investor's Business Daily on MSN
Psychedelics-tied GH skyrockets on FDA go-ahead for depression drug
Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback